Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue: +10.6%
EPS: −104.4%
Free cash flow: −69.3%
Total debt: +16.0%

Quarter to September 2026, against a year earlier

248.43 4.50 +1.84%

Follow BIIB

Alert me

Market cap: $36.1B
P/E: 104×
Fwd P/E: 47.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.13
Beneish M: −2.67
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Biogen Inc. 8-K filed Mar 11, 2026

Period ended Mar 11, 2026 · Filed Mar 11, 2026 · accepted 5:28 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Red flags

Officer departure Mar 11, 2026
Biogen Inc. reported the departure of an officer or director

8-K filed Mar 11, 2026 · The filing · sec.gov